Rumen Stefanov Filev

Dr. Rumen Stefanov Filev

MEDICAL UNIVERSITY, Sofia, Sofia-Grad, Bulgaria
+4
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 March 2025 in Nephrology Dialysis Transplantation
Verified
Journal Article
Open access
CFCharles J Ferro
Charles J Ferro
CWChristoph Wanner
Christoph Wanner
VLValerie Luyckx
Valerie Luyckx
KSKate I Stevens
Kate I Stevens
SCSofia Cerqueira
Sofia Cerqueira
Raymond VanholderRaymond Vanholder
Raymond Vanholder
Kidney disease is a global health priority affecting >850 million people worldwide. This number is projected to increase over the coming decades given the increasing prevalence of diabetes, hypertension and obesity and the aging population. Chronic kidney disease (CKD) can reduce both life expectancy and quality of life and is intricately linked with cardiac and metabolic health—the cardiovascular-kidney-metabolic multimorbidity syndrome. With early recognition of risk, CKD can be prevented and with timely case finding, early diagnosis and early intervention, its progression can be halted or slowed. The European Renal Association has established the Strong Kidneys Task Force, with the main purpose of creating awareness about the importance of kidney health for individual and population health. In collaboration with the European Kidney Health Alliance and the European Kidney Patients Federation, the ABCDE campaign will empower communities and individuals to remind their healthcare providers to assess their risk of kidney disease. ABCDE asks five simple questions about health status that only the healthcare system can provide: A) Do I have Albumin in my urine? B) What is my Blood pressure? C) What is my Cholesterol? D) Do I have Diabetes? E) What is my current kidney function (Estimated glomerular filtration rate)? This advocacy text aims to inform individuals, communities and front line healthcare workers that capturing the risk of kidney, cardiac and metabolic health is simple, makes sense, is logical and will save lives. Although making meaningful change will take time and involve major personal and societal changes, the first step really is as easy as ABCDE!

14 February 2025 in Microorganisms
Verified
Journal Article
Open access
PDF file
Rumen Stefanov FilevRumen Stefanov Filev
Rumen Stefanov Filev
MLMila Lyubomirova
Mila Lyubomirova
BBBoris Iliev Bogov
Boris Iliev Bogov
AKAlexander Kolevski
Alexander Kolevski
VPVictoria Pencheva
Victoria Pencheva
Lionel ROSTAINGLionel ROSTAING
Lionel ROSTAING
Urinary tract infections (UTIs) are among the most prevalent bacterial infections, with Klebsiella pneumoniae emerging as a significant multidrug-resistant pathogen, particularly in healthcare settings. The frequent utilization of β-lactams and fluoroquinolones has contributed to the reduced clinical application of trimethoprim-sulfamethoxazole (TRS). Nevertheless, this reduced use may have preserved its efficacy as a second-line therapy. The aim of this study is to determine whether TRS can be a cost-effective long-term solution for patients with multidrug-resistant K. pneumoniae UTIs. This study evaluated the effectiveness of a structured, long-term TRS regimen in 11 patients with recurrent K. pneumoniae UTIs who had failed at least two prior antibiotic treatments. Patients were carefully selected, and the collected data were analyzed using descriptive analysis. The findings demonstrated microbiological eradication and symptomatic relief in all patients, with only one case of a delayed allergic reaction. All patients had a negative urine microbiology analysis after at least two unsuccessful treatment attempts over a period of 6 to 18 months. These results underscore TRS’s potential as a cost-effective and efficient second-line treatment, particularly in settings with limited therapeutic options. Its affordability, manageable side effect profile, and ability to target biofilm-associated infections further highlight its therapeutic value.

Verified
Journal Article
Open access
PDF file
Rumen Stefanov FilevRumen Stefanov Filev
Rumen Stefanov Filev
Lionel ROSTAINGLionel ROSTAING
Lionel ROSTAING
MLMila Lyubomirova
Mila Lyubomirova
BBBoris Iliev Bogov
Boris Iliev Bogov
KKKrasimir Kalinov
Krasimir Kalinov
DSDobrin Avramov Svinarov
Dobrin Avramov Svinarov
Regarding COVID-19 infection, Bulgaria has one of the lowest rates of vaccination in Europe, and its COVID-19-related mortality rate has been one of the highest in the European Union. Chronic kidney disease (CKD)-COVID-19 patients are at higher risk of developing acute kidney injury (AKI) and death after hospital admission. This single-center prospective cohort study from Bulgaria included 120 in-patient COVID-19 subjects of whom 70 had CKD and 50 normal renal function. Diabetes mellitus, hypertension, obesity, and cardiovascular disease were statistically more prevalent in the CKD group as compared to the non-CKD group. At admission, D-dimer, creatinine, and urea levels were significantly higher in the CKD group, whereas estimated glomerular-filtration rate was significantly lower as compared to the non-CKD patients. During hospitalization, 23 patients (19.1%) died, of which 19 were in the CKD group (p-value = 0.0096); in addition, 38 developed AKI (31.6%), of which 31 were in the CKD group (p-value = 0.0006). Using binary logistic regression, being male, having experienced AKI, and not having been treated with remdesivir were independent risk factors for COVID-19-induced mortality. Regarding risk of AKI, having had COVID-19-related symptoms for more than 6 days before admission, having CKD at baseline, and having not received remdesivir therapy were independent predictive factors for developing AKI after admission.
1

Verified
Journal Article
Open access
PDF file
Rumen Stefanov FilevRumen Stefanov Filev
Rumen Stefanov Filev
MLMila Lyubomirova
Mila Lyubomirova
BBBoris Iliev Bogov
Boris Iliev Bogov
KKKrasimir Kalinov
Krasimir Kalinov
Julieta HristovaJulieta Hristova
Julieta Hristova
Lionel ROSTAINGLionel ROSTAING
Lionel ROSTAING
In this prospective study, we assessed biomarkers of inflammation (IL-6 and SAA) from the serum of 120 COVID-19 patients, of whom 70 had chronic kidney disease. All the samples were taken at emergency-department (ED) admission. Our goal was to relate the biomarkers to the results of death and acute kidney injury. All the patients underwent chest computer tomography to estimate the severity score (0–5), which was performed at hospital admission. Finally, biomarkers were also evaluated in a healthy control group and in non-COVID-19-CKD patients. IL-6 and SAA were statistically different between the subgroups, i.e., they were significantly increased in patients with COVID-19. Both of the biomarkers (IL-6 and SAA) were independently associated with mortality, AKI and a higher grade of pathological changes in the lung’s parenchyma. Both high baseline levels of IL-6 and SAA on hospital admission were highly correlated with a later ventilatory requirement and mortality, independent of hospital stay. Mortality was found to be significantly higher when the chest CT severity score was 3–4, compared with a severity score of 0–2 (p < 0.0001). Conclusions: at the admission stage, IL-6 and SAA are useful markers for COVID-19 patients with CKD.

22 August 2025 in Antibiotics
Verified
Journal Article
Open access
PDF file
Rumen Stefanov FilevRumen Stefanov Filev
Rumen Stefanov Filev
BBBoris Iliev Bogov
Boris Iliev Bogov
MLMila Lyubomirova
Mila Lyubomirova
Lionel ROSTAINGLionel ROSTAING
Lionel ROSTAING
Background/Objectives: The rise in urinary tract infections caused by multidrug-resistant (MDR) bacteria presents a serious public health challenge across the Balkans, a region already burdened by aging populations, healthcare resource limitations, and fragmented antimicrobial surveillance systems. Methods: This review explores the epidemiology, risk factors, and consequences of MDR UTIs, particularly in the context of the COVID-19 pandemic, which significantly accelerated antimicrobial resistance (AMR) due to widespread, inappropriate antibiotic use. Results: The paper discusses region-specific data on resistance trends, highlights the gaps in diagnostic infrastructure, and evaluates emerging clinical strategies including antimicrobial stewardship (AMS), rapid diagnostic technologies, novel antibiotics, and non-antibiotic alternatives such as bacteriophage therapy and vaccines. Conclusions: Policy recommendations are provided to strengthen surveillance, promote evidence-based treatment, and ensure equitable access to diagnostic and therapeutic tools. A multidimensional and regionally coordinated response is essential to curb the MDR UTI burden and safeguard public health across the Balkans.

5 June 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
Rumen Stefanov FilevRumen Stefanov Filev
Rumen Stefanov Filev
MLMila Lyubomirova
Mila Lyubomirova
BBBoris Iliev Bogov
Boris Iliev Bogov
KKKrasimir Kalinov
Krasimir Kalinov
Julieta HristovaJulieta Hristova
Julieta Hristova
Lionel ROSTAINGLionel ROSTAING
Lionel ROSTAING
Post-acute sequelae of SARS-CoV-2 (PASC) is a significant health concern, particularly for patients with chronic kidney disease (CKD). This study investigates the long-term outcomes of individuals with CKD who were infected with COVID-19, focusing on their health status over a three-year period post-infection. Data were collected from both CKD and non-CKD patients who survived SARS-CoV-2 infection and were followed for three years as part of a research study on the impact, prognosis, and consequences of COVID-19 infection in CKD patients. In this prospective cohort study, we analyzed clinical records, laboratory findings, and patient-reported outcomes assessed at intervals during follow-up. The results indicated no permanent changes in renal function in any of the groups analyzed, although patients without CKD exhibited faster recovery over time. Furthermore, we examined the effect of RAAS-blocker therapy over time, finding no influence on PASC symptoms or renal function recovery. Regarding PASC symptoms, most patients recovered within a short period, but some required prolonged follow-up and specialized post-recovery management. Following up with patients in the post-COVID-19 period is crucial, as there is still insufficient information and evidence regarding the long-term effects, particularly in relation to CKD.